Back to Search
Start Over
Clonal Hematopoiesis and Risk of Progression of Heart Failure With Reduced Left Ventricular Ejection Fraction
- Source :
- Journal of the American College of Cardiology. 77:1747-1759
- Publication Year :
- 2021
- Publisher :
- Elsevier BV, 2021.
-
Abstract
- Clonal hematopoiesis driven by somatic mutations in hematopoietic cells, frequently called clonal hematopoiesis of indeterminate potential (CHIP), has been associated with adverse cardiovascular outcomes in population-based studies and in patients with ischemic heart failure (HF) and reduced left ventricular ejection fraction (LVEF). Yet, the impact of CHIP on HF progression, including nonischemic etiology, is unknown.The purpose of this study was to assess the clinical impact of clonal hematopoiesis on HF progression irrespective of its etiology.The study cohort comprised 62 patients with HF and LVEF 45% (age 74 ± 7 years, 74% men, 52% nonischemic, and LVEF 30 ± 8%). Deep sequencing was used to detect CHIP mutations with a variant allelic fraction2% in 54 genes. Patients were followed for at least 3.5 years for various adverse events including death, HF-related death, and HF hospitalization.CHIP mutations were detected in 24 (38.7%) patients, without significant differences in all-cause mortality (p = 0.151). After adjusting for risk factors, patients with mutations in either DNA methyltransferase 3 alpha (DNMT3A) or Tet methylcytosine dioxygenase 2 (TET2) exhibited accelerated HF progression in terms of death (hazard ratio [HR]: 2.79; 95% confidence interval [CI]: 1.31 to 5.92; p = 0.008), death or HF hospitalization (HR: 3.84; 95% CI: 1.84 to 8.04; p 0.001) and HF-related death or HF hospitalization (HR: 4.41; 95% CI: 2.15 to 9.03; p 0.001). In single gene-specific analyses, somatic mutations in DNMT3A or TET2 retained prognostic significance with regard to HF-related death or HF hospitalization (HR: 4.50; 95% CI: 2.07 to 9.74; p 0.001, for DNMT3A mutations; HR: 3.18; 95% CI: 1.52 to 6.66; p = 0.002, for TET2 mutations). This association remained significant irrespective of ischemic/nonischemic etiology.Somatic mutations that drive clonal hematopoiesis are common among HF patients with reduced LVEF and are associated with accelerated HF progression regardless of etiology.
- Subjects :
- Male
medicine.medical_specialty
Population
030204 cardiovascular system & hematology
DNA Methyltransferase 3A
Dioxygenases
Ventricular Dysfunction, Left
03 medical and health sciences
0302 clinical medicine
Germline mutation
Cause of Death
Proto-Oncogene Proteins
Internal medicine
medicine
Humans
DNA (Cytosine-5-)-Methyltransferases
Prospective Studies
030212 general & internal medicine
Mortality
Adverse effect
education
Aged
Heart Failure
education.field_of_study
Ejection fraction
business.industry
Tet methylcytosine dioxygenase 2
Hazard ratio
Prognosis
medicine.disease
DNA-Binding Proteins
Hospitalization
Spain
Heart failure
Mutation
Disease Progression
Cardiology
Etiology
Female
Clonal Hematopoiesis
Cardiology and Cardiovascular Medicine
business
Subjects
Details
- ISSN :
- 07351097
- Volume :
- 77
- Database :
- OpenAIRE
- Journal :
- Journal of the American College of Cardiology
- Accession number :
- edsair.doi.dedup.....9a87d562f1076311556532c1f7052452